Introduction {#s1}
============

Breast cancer is the second most common type of cancer and a leading cause of death among women worldwide ([@B14]; [@B67]). Due to its heterogeneous nature, different approaches have been used to classify its molecular subtypes ([@B22]). Recent research has shown that breast cancer can be categorized into four subtypes, based on the regulatory activity of molecular receptors like estrogen, progesterone and human epidermal growth factor receptor 2 (HER2) ([@B9]; [@B3]; [@B33]). The four subtypes are Luminal A, Luminal B, HER2-Enriched and Basal-Like. In the Luminal A (LA) subtype, estrogen and progesterone receptors are positive and HER2 receptor is negative. On the other hand, in Luminal B (LB) subtype, estrogen and progesterone receptors are positive, and HER2 receptor can be either positive or negative. In case of HER2-Enriched (HER2-E) subtype, HER2 receptor is positive and estrogen and progesterone receptors are negative. While in Basal-Like (BL) subtype, which is also known as triple-negative breast cancer, all three receptors are negative. The Luminal A (LA) breast cancer is the most prevalent, constituting 50--70% of female breast cancer cases ([@B24]; [@B45]), while the latter three subtypes are less common, constituting approximately 10--20% of all cases for Luminal B and Basal-Like, and 5--20% for HER2-Enriched. The presence of one or more of these receptors suggests that a treatment targeting their pathways might be effective, thus the subtype identification and subtype-aware research are needed. For instance the HER2-Enriched subtype tumors can be often effectively treated with therapies aimed at the HER2 protein ([@B13]). The breast cancer subtypes also vary in their clinical characteristics. For example, HER2-Enriched cancers tend to grow faster than Luminal A or B cancers and the outlook is usually worse. Crucially, it has been found that each subtype possess different expression profiles of miRNAs ([@B68]; [@B33]).

MiRNAs are non-coding RNA molecules of length 19-22 nucleotides, first discovered in *Caenorhabditis elegans* ([@B47]). Subsequently a range of studies revealed their important cellular functions ([@B5]; [@B75]). They are responsible for post-transcriptional gene regulation: they bind with their targeted mRNAs and degrade them, and as a result those targeted mRNAs are not able to take part in protein formation. Over the years, researchers were trying to understand the involvement of miRNAs in different malignancies ([@B62]; [@B58]; [@B35]) including, most importantly for this work, breast cancer ([@B71]; [@B44]). The advancement of Next Generation Sequencing (NGS) techniques ([@B73]), such as miRNA-seq, provided the data for more extensive studies of miRNAs. Subsequently it has been show in many studies, that genetic components such as miRNAs play a significant role in development, growth and metastasis of breast cancer ([@B15]). In this regard, a review ([@B71]) was carried out to find the functions of miRNAs associated with breast cancer and discuss their potential clinical uses. On the other hand, [@B46] focused on the role that miRNAs play in breast cancer, as well as discussed their potential as prognostic and predictive biomarkers. Moreover, breast cancer associated miRNAs were identified in order to understand the impact of expression change in this cancer type ([@B40]). In [@B77], the importance of the oncogene and tumor suppressor miRNAs associated with breast cancer are studied and developments in therapies are discussed, [@B44] conducted a survey on the recent trends of miRNA in breast cancer, focused on the association of miRNAs in particular breast cancer subtypes. For this purpose, [@B55] proposed an approach, in which multiple microarray datasets were used to obtain a set of subtype-specific miRNAs. Studies also propose machine learning methods: [@B64] provide a method based on support vector machines and feature selection to predict cancer stage. Finally, a review ([@B2]) focused on circulating and tissue-specific miRNAs as biomarkers.

One of the key methods in studying the role of miRNAs in breast cancer is survival analysis. Several tools have been developed to perform survival analysis, including Kaplan-Meier Plotter ([@B31]), BreastMark ([@B50]) or SurvMicro ([@B1]). These, however, can be used on microarray datasets, and do not make full use of the NGS data. Among the tools that use such data, are PROGgeneV2 ([@B30]), which focuses on genes, and PROGmiR ([@B29]) which allows for comparison of survival between high and low expression groups, but does not relay information about cancer subtypes. Finally, integrated solutions begin to emerge, like KM-express ([@B16]), that combines survival data as well as gene and cell line expression. Overall, majority of the tools and studies are still concerned about the functional and expression change of miRNAs associated with breast cancer, but the survival analysis of those miRNAs for breast cancer subtypes is limited to the best of our knowledge. Moreover, while studies employ survival analysis at the validation step, using survival data to identify candidate miRNAs is not common. This fact motivated us to conduct the present study on survival analysis using the NGS-provided high-throughput expression and clinical data of miRNAs associated with breast cancer subtypes.

To address the above fact, we propose a method of identifying miRNAs related to breast cancer and its intrinsic subtypes based on survial analysis. We use the Kaplan-Meier estimator ([@B37]; [@B34]) and the log-rank test ([@B8]; [@B42]) to rank the miRNAs by their influence to the patient survival in each breast cancer subtype. The results of the survival analysis provide us with four different sets of miRNAs with their rank based on the difference of hazard ratio ([@B65]), and p-value of the log-rank test. By selecting 100 miRNAs for each subtype and intersecting the lists, five different sets of miRNAs are prepared and named as four-star and one-star miRNAs. The four-star miRNAs are involved in all four subtypes, which means that this set of miRNAs can be used to discriminate the tumor and control samples of breast cancer. On the other hand, the four one-star miRNAs sets contain miRNAs specific to the subtypes such as Luminal A, Luminal B, HER2-Enriched and Basal-Like. These one-star miRNAs can be helpful for the identification of breast cancer subtypes.

In order to validate our findings computationally, we use seven well-known machine learning methods: Logistic Regression (LR, [@B34]), Decision Tree (DT, [@B63]), Artificial Neural Network (ANN), also known as Multilayer Perceptron ([@B36]), Support Vector Machine with linear kernel (SVM, [@B6]), K-Nearest Neighbors (K-NN, [@B43]), Random Forest (RF, [@B59]), and finally Naive Bayes Classifier (NB, [@B4]). Using these methods we performed five 2-class classification tasks and obtained the average accuracy of 95%, 68%, 73%, 81% and 77% for four-star and one-star miRNAs, respectively. We also compared these results, with the accuracy obtained on the sets of miRNAs from other studies, where the four-star miRNAs identified by us provided superior performance on our expression dataset. Next, we investigate the changes in expression of the selected miRNAs in different stages of breast cancer. We identify 10 miRNAs that exhibit variable expression in cancer stages I and II, and for 8 of which there is an increase as the stage progresses. In order to perform biological validation we analyze the networks of miRNAs, genes targeted by those miRNAs, and transcription factors (TFs), that target the miRNAs. To do this, we gradually refine the sets of miRNAs, genes and TFs, incorporating mRNA expression data, to obtain a network of closely interacting miRNAs, genes, and TFs that are all associated with breast cancer. As a result, we find several regulatory circuits, in which a miRNA targets a gene, that produces a transcription factor, that targets the same miRNA. We also analyze protein-protein interaction networks for the refined set of transcription factors. Finally, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and gene ontology (GO) enrichment analysis is performed, where we find cancer-related pathways and GO terms to be significantly enriched in genes targeted by the four-star and one-star miRNAs.

Materials and Methods {#s2}
=====================

This section describes briefly the Kaplan-Meier and Nelson-Aalen estimators, the Log-Rank Test, the preparation of the dataset and the proposed framework.

Survival Analysis {#s2_1}
-----------------

One of the widely used non-parametric methods for analyzing survival is the Kaplan-Meier (KM) estimator ([@B18]; [@B37]; [@B69]). The KM estimator refers to a certain population and estimates the survival function *S*(*t*), describing the probability of a certain event (in our case, a patient's death) happening before a certain point in time *t*, as given in the Equation 1.
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where *T* is the random variable representing the time of death. A less steep shape of survival function means better prognosis for the population, for which the function has been estimated. The Kaplan-Merier estimator is defined as in Equation 2.

S

\^

KM

(

t

)

=

Π

k

:

t

k

≤

t

(

1

−

E

k

N

k

)

where, *t* *~k~* is the time when at least one event (i.e. death) occurred, *E* *~k~* is the number of events occurring at time *t* *~k,~* and the so-called "individuals known to survive" at *t* *~k~* (event of death not occurred, or right-censored) is expressed by *N* *~k~*. The expression data, along with the status and last days to follow up information, is used to compute the KM plots. The log-rank test is a non-parametric statistical test used to compare the survival curves of the two samples. The test statistic is described by Equation 3,
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where *O* *~ik~* and *E* *~ik~* are the observed and expected numbers of events (deaths) in group *i* (one of the two) at time *k* = 1,..., *T*. The test statistic *Z* converges to the normal distribution as *T* approaches infinity. The null hypothesis is that there is no difference between the populations in the probability of an event at any time point. While the log-rank test provides a p-value for the difference between groups, it does not yield an estimate of the effect size. For this purpose, we compute the hazard ratio (HR): the ratio of the hazard rates (probabilities of death at a give time) in the two compared groups of patients. Taking our data as an example: if *HR* \> 1, then the high expression group has a higher chance of dying at any given time point. Under the null hypothesis of the log-rank test, i.e. when no difference in the probability of death between the two groups, the hazard ratio is equal to 1.

For comparison, we also include another non-parametric method of analyzing survival, named as Nelson-Aalen estimator ([@B20]; [@B10]). It estimates the cumulative hazard rate Λ(*t*), which is given in the Equation 4:
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The Nelson-Aalen estimator has the form given in Equation 5, with the similar symbols as mentioned in the Kaplan-Meier estimator.
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Data Preparation {#s2_2}
----------------

The expression and clinical data of miRNA-seq of breast invasive carcinoma (BRCA) is obtained from The Cancer Genome Atlas ([@B72]). TCGA provides miRNA-seq data in the form of reads per million (RPM) of 842 patients. However, the cancer subtype information is provided only for 231 patients: 190 with breast cancer and 41 controls. For this dataset, the subtype categorization based on Prediction Analysis of Microarray 50 genes (PAM 50) is taken ([@B54]). The statistics for each breast cancer subtype are provided in [**Table 1**](#T1){ref-type="table"}. With this expression data, we have the clinical information such as age, gender, last day to followup and status (alive or dead). Moreover, we select only those miRNAs for which at least 60% expression values are non-zero.

###### 

Statistics of four breast cancer subtypes and control samples.

  Subtype         Code      Sample size   Average age   Average days to last follow-up
  --------------- --------- ------------- ------------- --------------------------------
  Luminal A       LA        86            56.96         1704.55
  Luminal B       LB        39            55.07         1431.86
  HER2-Enriched   HER2-E    24            52.87         1307.12
  Basal-Like      BL        41            56.41         1402.34
  Control         Control   41            54.73         1632.60

Method {#s2_3}
------

[**Figure 1**](#f1){ref-type="fig"} shows the framework of our method in detail. First, we perform survival analysis using the KM method separately for each cancer subtype. For each subtype of breast cancer, we combine the set of patients having the expression of miRNA in cancer subtype with the controls. With such data we enter to the survival analysis, where patients are split into two balanced groups, based on the high-expression (above median) and low-expression (below median) of miRNA. For these two groups, we use KM estimator and log-rank test to obtain the hazard ratio (HR) and p-value. Using these statistics we create four ranking lists of miRNAs (one for each breast cancer subtype), based on the difference of hazard ratio and p-value, from highest to lowest. We then select 100 top miRNAs from each of the four subtype-related lists. In this way, we obtain filtered lists of miRNAs, each of which is most related to one of the breast cancer subtypes. A given miRNA can be present in any of these four lists related to the subtypes. In this study we focus on sets of miRNAs obtained by analyzing the intersection of the four lists. These are: the four-star miRNAs which are present in all lists, and one-star miRNAs, that are present only in a single list. The four-star miRNAs are considered to be relevant in all subtypes, while the one-star miRNAs are subtype-specific.

![Framework of proposed method.](fgene-10-01047-g001){#f1}

Finally, in order to rank the four-star miRNAs, we use an objective function Ψ, which provides a measure of relevance incorporating both statistical significance in terms of p-value and strength of influence of miRNA to the subtypes, i.e. hazard ratio. The objective function Ψ is defined in Equation 6 for each miRNA as sum of the difference of hazard ratio and p-value over the four subtypes.

Ψ

=

Σ

i

=

1

S

(

H

R

i

−

p

\-

valu

e

i

)

where *HR* *~i~* and *p-value* *~i~* are hazard ratios and p-values obtained for a given miRNA for the *i*-th cancer subtype and *S* is the number of subtypes i.e. equal to 4.

For the computational verification of the miRNAs, we use seven popular machine learning methods (Logistic Regression, Decision Tree, Artificial Neural Network, Support Vector Machine, K-Nearest Neighbour, Random Forest and Gaussian Naive Bayes Classifier) to assess the relevance of the four-star and one-star miRNAs in predicting breast cancer and distinguishing its type. As an input for the classifiers, we use the expression datasets of patients, in order to perform two different experiments. First, for the four-star miRNA set, we perform binary classification, by differentiating between tumor vs. control cases, without the division into different breast cancer subtypes. This is because the four-star miRNAs are related to all subtypes. Then, for each set of one-star miRNAs, we train the classifiers to distinguish the patients with the particular cancer subtype vs. all other patients (those with other breast cancer subtypes and controls). Moreover, we compare the accuracy of the above machine learning methods on our four-star miRNA set, to other sets of miRNAs proposed in the literature as either biomarkers or otherwise associated with breast cancer. The analysis is conducted in exactly the same fashion as with our miRNAs, as described above. Only those sets of miRNAs proposed by other studies are used, for which expression data existed in the TCGA dataset. These studies are listed along with the results.

Results and Discussion {#s3}
======================

In this section, we first describe the results of miRNA selection procedure based on survival analysis, through which we obtain the four-star and one-star miRNAs. Next, we discuss the accuracy of classifiers that distinguish cancer patients from controls, as well as differentiate the breast cancer subtypes, based on the miRNAs expression data. Finally, we validate biological significance of the five miRNA sets identified by our method.

In order to validate our results, we perform the following analyses: first, we use miRTarBase ([@B17]) for finding miRNA-targeted genes, TransmiR v2.0 ([@B72a]) for finding transcription factors targeting the miRNAs, and TRRUST v2 ([@B32]) for transcription factor's targeted genes. This data, after refinement, is used to create regulatory networks of miRNAs, genes and TFs. Next, we create protein-protein interaction (PPI) networks of the transcription factors targeting the miRNAs, and identified highly connected nodes, that are important in the network. For this purpose, the STRING database ([@B70]) is used. Thereafter, we perform Kyoto Encyclopedia of Genes and Genomes (KEGG, [@B39]) pathway analysis, in order to find pathways influenced by the miRNAs' targeted genes. Finally, Gene Ontology enrichment analysis is performed, to find the biological processes, cellular components, and molecular functions on which the miRNAs have influence through their targeted genes. Both pathway and gene ontology analysis is performed using STRING database as well.

Selection of miRNAs Using Survival Analysis {#s3_1}
-------------------------------------------

We perform the survival analysis using MATLAB software ([@B51]). From the initial set of patients, we retain only those, for whom two conditions are met: 1) the breast cancer subtype information is known and 2) at least 60% of the expression values are non-zero. Using these criteria, 190 patients are entered into the analysis, forming four groups for the breast cancer subtype, as described in the Method section. Each group is divided into high and low expression subgroups by median split, and hazard ratio is computed between the low and high expression groups. The log-rank test comparing the two groups is also performed to obtain a p-value. Moreover, the survival functions of the high and low-expression groups are estimated using the KM estimator, and survival plots are created. Then, four rankings (one for each breast cancer subtype) of the initial 587 miRNAs are created, based on difference of the hazard ratio and p-value relevant to the given subtype, and the top 100 miRNAs are taken from each list. We inspect, how these lists of 100 miRNAs intersect, since a given miRNA can be present in more than one list, and the intersection is visualized using a Venn diagram in [**Figure 2**](#f2){ref-type="fig"}.

![Venn diagram of top 100 miRNAs for four breast cancer subtypes.](fgene-10-01047-g002){#f2}

We note the 44 miRNAs present in all four lists as constituting the set of four-star miRNAs. Subtype-specific sets (miRNAs present in exactly one of the lists) are also identified, comprising 12 miRNAs for the LA subtype, 14 for LB subtype, 9 for the HER2-E subtype, and finally 15 for the BL subtype. The results of survival analysis of four-star miRNAs are presented in [**Table 2**](#T2){ref-type="table"}. Apart from the value of the previously described scoring function, the hazard ratios and corresponding p-values for each of the cancer subtype are reported in the same table.

###### 

The four-star miRNAs ranked based on the sum (Ψ) of the difference of hazard ratio and p-value over the four breast cancer subtypes, along with the PubMed ID.

  miRNA               LA      LB      HER2-E   BL      Ψ Score   PubMed ID                            
  ------------------- ------- ------- -------- ------- --------- ----------- ------- ------- -------- ----------
  hsa-miR-365a-3p     3.308   0.001   2.467    0.044   3.503     0.007       4.851   0.000   14.076   23592263
  hsa-miR-452-5p      2.311   0.019   3.039    0.012   4.922     0.000       2.367   0.065   12.542   23592263
  hsa-miR-378a-3p     2.318   0.019   2.910    0.017   3.003     0.020       4.037   0.002   12.210   23592263
  hsa-miR-215-5p      2.127   0.039   2.636    0.037   2.158     0.101       4.655   0.001   11.399   23592263
  hsa-miR-103a-3p     3.664   0.000   2.182    0.086   3.713     0.004       1.572   0.376   10.664   21572407
  hsa-miR-224-5p      3.193   0.001   3.435    0.005   2.372     0.061       1.095   0.996   9.031    23399735
  hsa-miR-335-3p      2.203   0.035   2.119    0.100   4.142     0.002       2.317   0.068   10.576   23592263
  hsa-miR-326         2.661   0.010   2.081    0.110   2.455     0.057       3.061   0.014   10.066   20216554
  hsa-miR-10a-5p      1.344   0.471   1.934    0.157   2.217     0.110       4.203   0.001   8.958    23622248
  hsa-miR-217         1.848   0.092   4.166    0.001   1.985     0.162       1.346   0.610   8.479    19008416
  hsa-miR-10b-3p      2.091   0.054   2.098    0.112   1.521     0.443       3.878   0.003   8.976    22012620
  hsa-miR-378a-5p     2.791   0.004   1.560    0.395   2.076     0.135       2.996   0.017   8.874    23592263
  hsa-miR-193a-5p     2.372   0.016   1.803    0.215   3.078     0.016       1.922   0.172   8.757    23446348
  hsa-miR-664a-3p     1.967   0.066   1.411    0.527   1.470     0.494       3.456   0.006   7.210    23592263
  hsa-miR-30c-2-3p    2.731   0.006   1.847    0.208   2.197     0.118       2.093   0.117   8.419    23592263
  hsa-miR-511-5p      2.245   0.030   2.316    0.064   1.956     0.176       2.366   0.064   8.549    23592263
  hsa-miR-143-3p      2.400   0.014   1.841    0.206   1.157     0.901       2.567   0.042   6.802    17504027
  hsa-miR-10b-5p      1.524   0.272   2.304    0.069   2.374     0.079       2.445   0.056   8.171    17898713
  hsa-miR-22-3p       2.148   0.038   2.715    0.025   1.099     0.992       1.786   0.237   6.456    20371350
  hsa-miR-140-3p      1.769   0.141   2.083    0.118   2.270     0.090       2.481   0.051   8.203    23446348
  hsa-miR-338-3p      2.806   0.005   1.644    0.313   1.885     0.181       1.164   0.879   6.121    25945841
  hsa-miR-451a        2.035   0.050   1.610    0.330   1.639     0.340       2.812   0.022   7.354    20227367
  hsa-miR-486-5p      2.263   0.027   1.380    0.554   1.565     0.401       2.603   0.035   6.793    23592263
  hsa-miR-28-3p       1.966   0.063   2.363    0.063   2.169     0.101       1.499   0.451   7.318    23592263
  hsa-miR-139-5p      1.709   0.167   1.685    0.293   1.791     0.253       2.641   0.033   7.080    21925125
  hsa-miR-125b-2-3p   1.869   0.089   1.821    0.223   0.986     0.850       2.683   0.034   6.162    23592263
  hsa-miR-100-5p      1.868   0.089   1.811    0.235   1.771     0.280       2.311   0.086   7.071    19739117
  hsa-miR-195-5p      1.547   0.253   1.351    0.608   1.430     0.550       2.642   0.036   5.524    18320040
  hsa-miR-584-5p      1.623   0.200   1.812    0.218   2.546     0.053       1.442   0.512   6.442    23446348
  hsa-let-7c-5p       1.835   0.099   1.821    0.223   1.118     0.972       2.224   0.094   5.610    17600087
  hsa-miR-574-3p      2.434   0.022   1.330    0.624   1.489     0.467       1.304   0.665   4.780    23592263
  hsa-miR-144-5p      2.184   0.032   1.239    0.747   1.387     0.574       1.822   0.214   5.065    26458302
  hsa-miR-145-5p      1.696   0.158   1.446    0.497   1.296     0.701       2.191   0.098   5.175    20160723
  hsa-let-7e-3p       2.092   0.054   1.159    0.875   1.460     0.502       1.491   0.449   4.322    24398324
  hsa-miR-24-1-5p     1.443   0.348   2.057    0.123   1.045     0.915       1.900   0.191   4.868    23592263
  hsa-miR-30a-3p      1.364   0.466   1.258    0.720   1.815     0.256       1.902   0.180   4.717    23592263
  hsa-miR-362-5p      1.584   0.222   2.059    0.117   1.646     0.333       1.316   0.657   5.277    24495516
  hsa-miR-339-5p      1.333   0.509   1.303    0.653   1.716     0.285       1.089   0.985   3.010    23592263
  hsa-miR-361-3p      1.992   0.071   1.485    0.445   1.381     0.584       0.933   0.967   3.723    23592263
  hsa-miR-30e-3p      1.518   0.280   1.748    0.253   1.327     0.656       1.076   0.977   3.504    23592263
  hsa-miR-145-3p      1.684   0.164   1.435    0.506   1.264     0.743       1.760   0.257   4.473    24398324
  hsa-miR-29a-3p      1.526   0.271   1.718    0.261   1.401     0.561       1.080   0.980   3.651    19850741
  hsa-miR-34a-5p      1.653   0.178   1.830    0.197   1.603     0.360       1.403   0.539   5.216    18834855
  hsa-miR-193b-5p     1.373   0.454   1.034    0.900   1.785     0.242       1.022   0.876   2.742    23446348

Overall, 26 out of 44 miRNAs are significant (*p-value* \< 0.05) after log-rank test for at least one cancer subtype. In all except one case there is a negative relation between survivability and the expression of the miRNA (*HR* \> 1). The exception was hsa-miR-361-3p for HER2-E subtype, where the *HR* = 0.933 and p-value = 0.967. Since the sample is not very large, and we were mainly interested in ranking based on hazard ratio, and not in the influence per se, we do not reject any miRNAs on the base of p-value, and proceed with biological validation. The Kaplan-Meier survival plots of top five miRNAs from the list of four-star miRNAs are shown in [**Figure 3**](#f3){ref-type="fig"} for each subtype. Similarly, survial plots of top four one-star miRNAs for each subtype are presented in [**Figure 4**](#f4){ref-type="fig"}, and the obtained statistics in [**Table 3**](#T3){ref-type="table"}. Both the Kaplan-Meier plots and the cumulative hazard ratio plots, created using Nelson-Aalen estimator, indicate in concordance, that increased expression increases breast cancer risk. The hazard ratio and p-value obtained from the log-rank test for 100 miRNAs of each subtype are reported in the [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}. Moreover, both Kaplan-Meier survival plots and cumulative hazard ratio plots using Nelson-Aalen estimator are provided in [**Supplementary Figures S1**](#SM1){ref-type="supplementary-material"}--[**S10**](#SM1){ref-type="supplementary-material"}.

![Survival plots of top five four-star miRNAs: **(A**--**D)**:hsa-miR-365a-3p, **(E**--**H)**:hsa-miR-452-5p, **(I**--**L)**:hsa-miR-378a-3p, **(M**--**P)**:hsa-miR-215-5p and **(Q**--**T)**:hsa-miR-103a-3p as mentioned in [**Table 2**](#T2){ref-type="table"} where blue line indicates low expression group and red line indicates high expression group.](fgene-10-01047-g003){#f3}

![Survival plots of top four one-star miRNAs for LA:**(A)** hsa-miR-30b-3p **(B)** hsa-miR-1247-5p **(C)** hsa-miR-221-3p **(D)** hsa-miR-186-5p LB:**(E)** hsa-miR-485-3p **(F)** hsa-miR-582-3p **(G)** hsa-miR-491-5p **(H)** hsa-miR-22-5p HER2-E:**(I)** hsa-miR-30c-5p **(J)** hsa-miR-26b-3p **(K)** hsa-miR-29c-5p **(L)** hsa-miR-19b-3p BL:**(M)** hsa-miR-199b-5p **(N)** hsa-miR-889-3p **(O)** hsa-miR-26b-5p **(P)** hsa-miR-214-3p subtypes as mentioned in [**Table 3**](#T3){ref-type="table"} where blue line indicates low expression group and red line indicates high expression group.](fgene-10-01047-g004){#f4}

###### 

The one-star miRNAs ranked based on the difference of hazard ratio and p-value for four breast cancer subtypes.

  miRNA             LA        miRNA     LB                                         
  ----------------- --------- --------- ------- ----------------- -------- ------- --------
  hsa-miR-30b-3p    1.461     0.354     1.107   hsa-miR-485-3p    2.073    0.116   1.956
  hsa-miR-1247-5p   1.458     0.352     1.105   hsa-miR-582-3p    1.892    0.179   1.713
  hsa-miR-221-3p    1.373     0.437     0.936   hsa-miR-491-5p    1.603    0.348   1.255
  hsa-miR-222-3p    1.363     0.478     0.885   hsa-miR-22-5p     1.588    0.352   1.236
  hsa-miR-1180-3p   1.362     0.477     0.885   hsa-miR-1249-3p   1.531    0.401   1.131
  hsa-miR-186-5p    1.332     0.505     0.827   hsa-miR-146b-3p   1.288    0.681   0.608
  hsa-miR-107       1.331     0.509     0.823   hsa-miR-374b-5p   1.260    0.713   0.546
  hsa-miR-505-3p    1.317     0.530     0.787   hsa-miR-151a-3p   1.209    0.795   0.414
  hsa-miR-455-5p    1.308     0.534     0.774   hsa-miR-152-3p    1.004    0.844   0.159
  hsa-miR-532-5p    1.221     0.689     0.532   hsa-miR-27b-5p    1.020    0.877   0.143
  hsa-miR-502-3p    1.217     0.689     0.528   hsa-miR-181a-3p   1.019    0.876   0.143
  hsa-miR-24-3p     1.208     0.689     0.519   hsa-miR-185-5p    1.027    0.889   0.138
                                                hsa-miR-1307-3p   1.054    0.940   0.114
                                                hsa-miR-425-3p    0.939    0.957   -0.019
  miRNA             HER2-E    miRNA     BL                                         
  HR                p-value   Ψ Score   HR      p-value           ΨScore           
  hsa-miR-30c-5p    1.746     0.295     1.451   hsa-miR-199b-5p   1.508    0.447   1.061
  hsa-miR-26b-3p    1.175     0.867     0.308   hsa-miR-889-3p    1.240    0.753   0.486
  hsa-miR-29c-5p    1.163     0.883     0.281   hsa-miR-26b-5p    1.230    0.769   0.461
  hsa-miR-19b-3p    1.128     0.941     0.187   hsa-miR-214-3p    1.145    0.907   0.238
  hsa-miR-20b-5p    1.019     0.871     0.148   hsa-miR-136-3p    0.999    0.836   0.163
  hsa-miR-874-3p    1.038     0.900     0.138   hsa-miR-134-5p    1.011    0.856   0.156
  hsa-miR-3127-5p   1.038     0.901     0.136   hsa-miR-101-5p    1.022    0.873   0.148
  hsa-miR-299-5p    1.059     0.941     0.118   hsa-miR-30b-5p    0.992    0.844   0.148
  hsa-miR-20a-3p    1.068     0.956     0.111   hsa-miR-542-3p    1.028    0.888   0.140
                                                hsa-miR-154-5p    1.060    0.947   0.114
                                                hsa-miR-375       1.066    0.958   0.108
                                                hsa-miR-409-5p    0.971    0.893   0.078
                                                hsa-miR-409-3p    0.929    0.972   -0.043
                                                hsa-miR-539-5p    0.925    0.984   -0.059
                                                hsa-let-7f-5p     0.920    0.993   -0.073

Selected miRNAs for Classification of Breast Cancer {#s3_2}
---------------------------------------------------

Using seven machine learning methods viz. Logistic Regression, Decision Tree, Artificial Neural Network, Support Vector Machine, K-Nearest Neighbour, Random Forest and Gaussian Naive Bayes Classifier, we perform five binary classification tasks by considering four-star and one-star miRNAs for which the results are presented in [**Table 4**](#T4){ref-type="table"}. The implementations of the algorithms is provided by the scikit-learn Python library version 0.19.1 ([@B57]), and the detailed parameters of each algorithm are reported in the [**Supplementary Table 2**](#SM1){ref-type="supplementary-material"}, by following the literature ([@B57]). For each breast cancer subtype, the machine learning methods are able to distinguish patients with that subtype from other breast cancer subtypes and controls, using the expression data of the relevant sets of four-star and one-star miRNAs, by achieving average accuracy of 95%, 68%, 73%, 81%, and 77% using 5-fold cross-validation. Among the seven machine learning methods, Random Forest achieves on average the highest accuracy of 84% over five sets of miRNAs. Moreover, the four-star set of miRNAs provides a higher average accuracy of the classifiers, than the sets that have been obtained from the literature, using the same expression data. Here 7 studies have been considered, and average accuracy (listed in [**Table 4**](#T4){ref-type="table"}) ranges from 77% to 94% on tumor vs control classification task.

###### 

Classification results of breast cancer using four-star miRNAs in comparison with other sets of miRNAs in the literature, as well as the results of one-star miRNAs. The four-star results are sorted according to average prediction accuracy. From other studies only those four-star miRNAs, for which expression data was available, are included.

  miRNA set            No. of Set of miRNA   LR      DT      ANN     SVM     K-NN    RF      NB      Average
  -------------------- --------------------- ------- ------- ------- ------- ------- ------- ------- ---------
  4-star (Our study)   44                    0.965   0.914   0.935   0.922   0.978   0.965   0.974   0.951
  \[55\]               23                    0.927   0.922   0.927   0.952   0.974   0.948   0.897   0.935
  \[9\]                12                    0.901   0.901   0.909   0.923   0.957   0.953   0.953   0.928
  \[64\]               3                     0.888   0.918   0.883   0.888   0.905   0.922   0.931   0.905
  \[71\]               2                     0.827   0.836   0.836   0.814   0.862   0.844   0.818   0.834
  \[2\]                3                     0.780   0.806   0.858   0.780   0.871   0.832   0.801   0.818
  \[44\]               2                     0.706   0.762   0.823   0.693   0.823   0.805   0.849   0.780
  \[77\]               3                     0.732   0.749   0.809   0.719   0.806   0.789   0.788   0.770
  1-star LA            12                    0.663   0.667   0.711   0.597   0.710   0.710   0.676   0.676
  1-star LB            14                    0.577   0.745   0.775   0.635   0.805   0.810   0.732   0.726
  1-star HER2-E        9                     0.649   0.827   0.736   0.771   0.896   0.901   0.858   0.805
  1-star BL            15                    0.701   0.792   0.762   0.740   0.809   0.827   0.731   0.766

Furthermore, the hierarchical clustering analysis has been performed, in the same schema as in the classification task, to visualize the comparison between miRNA expression in cancer patients and controls for the four-star miRNAs and between the cancer subtype and control for one-star miRNAs. The resulting heatmaps are provided in the [**Supplementary Figures 11**](#SM1){ref-type="supplementary-material"} and [**12**](#SM1){ref-type="supplementary-material"}.

Selected miRNAs for the Analysis of Cancer Stage {#s3_3}
------------------------------------------------

We analyze the relationship between miRNA expression and the stage of breast cancer, using the R statistical package ([@B60]). We assign each patient to one of breast cancer stages (I-IV), according to the AJCC stage data obtained from the TCGA database. Moreover, we restrict the analyses to stages I and II, as it is more clinically relevant to detect cancer in earlier stages. For the one-star miRNAs, only patients having that particular cancer subtype are taken, while for the four-star miRNAs all patients, for whom stage data were available, are included. The statistics of the samples of breast cancer stage for different subtypes are presented in the [**Supplementary Table 3**](#SM1){ref-type="supplementary-material"}.

For each miRNA, we execute a one-way ANOVA, with the independent variable being the stage of cancer, and the dependent variable being the expression value of the miRNA. We find, among the four-star and one-star miRNA sets, 10 miRNAs with significant (*p-value* \< 0.05) expression change between the stages. The four-star miRNAs identified are: hsa-miR-224-5p (p-value = 0.004), hsa-miR-574-3p (p-value = 0.028), hsa-miR-339-5p (p-value = 0.033), hsa-miR-584-5p (p-value = 0.035), hsa-miR-452-5p (p-value = 0.040) and hsa-miR-10b-5p (p-value = 0.050). Moreover, in the Luminal A one-star miRNA set, hsa-miR-24-3p (p-value = 0.024), hsa-miR-455-5p (p-value = 0.037) and hsa-miR-505-3p (p-value = 0.038) are having significant p-values. Finally, in the HER2-Enriched one-star miRNA set, the hsa-miR-30c-5p (p-value = 0.029) is significant. For all except hsa-miR-30c-5p and hsa-miR-10b-5p miRNAs, the expression increases with stage. This increase is concordant with the increased hazard in the group with high expression of these miRNAs, as indicated by the survival analysis, and implies, that the miRNA expression increases with stage progression. For example, overexpression of hsa-miR-10b-5p is known to trigger invasion and metastasis of breast cancer ([@B49]), which can be inhibited by silencing this miRNA ([@B48]) in a mouse model. Different survival characteristics of high and low expression groups can also induce changes in stage expression of miRNAs, as patients with high hazard value progress more rapidly through stages of cancer. On the other hand, an expression change in a given cancer stage can indicate a potential miRNA, that is associated specifically with a given stage. The plots showing the miRNA expression in different cancer stages are given in [**Figure 5**](#f5){ref-type="fig"}. The full results of ANOVA are available in the [**Supplementary Table 4**](#SM1){ref-type="supplementary-material"}, as well as plots for all miRNAs in four-star and one-star sets are given in [**Supplementary Figure 15**](#SM1){ref-type="supplementary-material"}.

![Expression of miRNAs in cancer stages I and II, for those 10 miRNAs, that have shown significant difference in expression. For the four-star miRNAs, these are: **(A)** hsa-miR-224-5p, **(B)** hsa-miR-574-3p, **(C)** hsa-miR-339-5p, **(D)** hsa-miR-584-5p, **(E)** hsa-miR-452-5p, **(F)** hsa-miR-10b-5p; For LA one-star miRNA set: **(G)** hsa-miR-24-3p, **(H)** hsa-miR-455-5p, **(I)** hsa-miR-505-3p; For HER-2: **(J)** hsa-miR-30c-5p](fgene-10-01047-g005){#f5}

Selected miRNAs for Regulatory Network Analysis {#s3_4}
-----------------------------------------------

In order to identify the genes that are targeted by miRNAs and TFs, and the TFs that target miRNAs for four-star and one-star miRNAs, we used recently published databases of miRTarBase, TRRUST and TransmiR respectively. Then we refine these three sets to select only those genes, TFs and miRNAs, that are closely related. The procedure is described below and visualized in [**Figure 6**](#f6){ref-type="fig"}.

-   Step 1: for the miRNAs in a given set (either four-star or one of the one-star) we identify the targeted genes.

-   Step 2: the TFs that target the miRNAs in the set are identified.

-   Step 3: for the obtained TFs we identify a smaller subset of targeted miRNAs.

-   Step 4: the genes targeted by this smaller subset of miRNAs is selected.

-   Step 5: the set of TFs associated with the genes identified in step 4.

-   Step 6: an intersection of the two sets of TFs (produced by steps 2 and 5) is computed. These TFs from both these sets target the initial miRNAs.

-   Step 7: we find the genes targeted by TFs from step 6.

-   Step 8: genes, in turn, are targeted by the initial set of miRNAs.

-   Step 9: the expression values of miRNAs are correlated with the mRNA expression, and only those mRNAs are selected, for which Pearson correlation is below −0.3.

-   Step 10: the TFs targeting genes corresponding to the mRNAs are found.

-   Step 11: the miRNA set is restricted by considering only the miRNAs targeted by TFs identified in the previous step.

![Diagrams representing the steps of refining the miRNAs, gene and TF sets. The steps 1-8 are, while the steps 9, 10 and 11 are based on negative correlation. **(A)** four-star miRNAs and one-star miRNAs for **(B)** LA, **(C)** LB, **(D)** HER2-E and **(E)** BL.](fgene-10-01047-g006){#f6}

The numbers of miRNAs, genes and TFs in each phase of the procedure is provided in [**Supplementary Table 5**](#SM1){ref-type="supplementary-material"}, and the details of each step, in the [**Supplementary Table 6**](#SM1){ref-type="supplementary-material"}.

We use these final, refined sets to create regulatory miRNA-Gene-TF networks, that show the relationships among the miRNAs, genes and transcription factors. These networks are given in [**Supplementary Figures 13**](#SM1){ref-type="supplementary-material"} and [**14**](#SM1){ref-type="supplementary-material"}. All such networks have been created for each miRNA set. However in this article, a combined network of miRNA-Gene-TF is shown in [**Figure 7**](#f7){ref-type="fig"}. This combined network shows all the miRNAs, genes, and TFs present in other five networks. For better visualization, each network is provided in two forms: in one, all the nodes (miRNAs, genes, TFs) are present, in the other, only those nodes are presented, that form loops, where the TF and a gene with the same name are both associated with the same miRNA.

![Regulatory networks of miRNAs (yellow rectangle), genes (purple ellipse) and transcription factors (blue octagon), created using the combined list of transcription factors. The network **(A)** contains all elements. Network **(B)** contians only the loops between miRNAs and same-named Genes and TFs](fgene-10-01047-g007){#f7}

Several important transcription factors are present in the combined networks, such as the MYC proto-oncogene protein, which is acting as an oncogene for breast cancer ([@B23]), or the estrogen receptor 1 (ESR1), highly relevant to breast cancer ([@B19]). Moreover, the breast cancer type 1 susceptibility protein (BRCA1), which acts as a tumor suppressor trough DNA repair ([@B26]) is present. Another node is the hypoxia-inducible factor 1-alpha encoded by HIF1A gene, whose abnormal expression is widely known to be involved in multiple cancers ([@B78]). On the other hand, the nuclear factor NF kappa B encoded by NFKB1 gene, suspected but not associated directly with breast cancer ([@B21]), is also present and interacting with other elements in the network, which may indicate an indirect relationship with this disease. The E2F1 and E2F3 transcription factors, implicated in breast cancer and other cancer types, are also present: E2F1 is promoting cancer cell proliferation ([@B7]), while overexpression of E2F3 can lead to development of cancer ([@B74]).

Subsequently, from the interaction results of miRNA-Gene-TF networks, we identify a set of regulatory circuits, where a certain miRNA targets a gene, and is targeted by a TF which is a product of the same gene and interacting with each other. For example, hsa-miR-100-5p targets *TP53* gene, which encodes the cellular tumor antigen p53, which is a tumor suppressor and alterations of which is associated with breast cancer ([@B11]; [@B12]). These circuits are shown in [**Figure 8**](#f8){ref-type="fig"}.

![Regulatory circuits identified from cross-referencing miRNA and TF targets for the four-star and one-star miRNAs. In each subfigure, a TF targets a miRNA, that in turn targets a Gene associated with that TF. Multiple miRNAs are combined in the plot for the same TF and gene. The miRNAs are represented by yellow rounded rectangles, genes by purple ellipses, and transcription factors by blue octagons.](fgene-10-01047-g008){#f8}

Selected miRNAs for Protein-Protein Interaction Network Analysis {#s3_5}
----------------------------------------------------------------

Furthermore, we look at protein-protein interaction (PPI) networks of the refined sets of proteins (TFs) that interact with the four-star and one-star miRNAs. Using STRING database we create six networks: one for each of the five sets of miRNA, and a combined network, using the transcription factors present in all of the five networks. All networks have highly significant enrichment p-values, indicating that significantly more interactions are present, than expected. The p-values are: 0.037 for Luminal A network, 5.88*e*−5 for Luminal B, 8.12*e*−5 for HER2-Enriched, 0.012 for Basal-Like, and less than 1.00*e*−16 for both the four-star network and the combined network. The combined network is presented in [**Figure 9**](#f9){ref-type="fig"}, while the individual networks are shown in [**Supplementary Figure 16**](#SM1){ref-type="supplementary-material"}. From each PPI network, the degree of every node (number of interactions of a given protein) is computed, and shown alongside each network in respective figure. Here, our focus is to identify proteins forming hubs in the PPI networks, i.e. those having relatively large number of interactions. These highly connected proteins can be seen as significant, as cancer-related proteins tend to have more interaction partners and be located close to central hubs ([@B38]). They often are the very transcription factors discussed in the previous section. It is to be noted that several proteins with high number of interactions have been found in the combined network, starting with the protein MYC, being the most interacting for the combined network, as well as for the networks corresponding to the four-star miRNA set, and the one-star LB, HER2-E, and BL sets. Next, the BRCA1 protein is present and highly connected in the combined network and the LB network. Moreover, the estrogen receptor 1 (ESR1) is also present an highly connected in the combined network, as well as in HER2-E and BL network. The most interacting for the Luminal A breast cancer subtype, is the HIF1A protein, also mentioned in the discussion of the regulatory networks. Finally, one moderately connected protein not present in the combined regulatory network is the Polycomb group protein EZH2, identified as a marker of aggressive breast cancer ([@B41]). The composition of the PPI networks is given in [**Supplementary Table 7**](#SM1){ref-type="supplementary-material"}, and the details of PPI interactions are in the [**Supplementary Table 8**](#SM1){ref-type="supplementary-material"}.

![The PPI network created for the combined set of transcription factors. The barplot shows the number of connections for the proteins. Colors of edges represent protein-protein association type, as indicated in the legend. Node colors are for aesthetic purposes.](fgene-10-01047-g009){#f9}

Selected miRNAs for KEGG Pathway Analysis {#s3_6}
-----------------------------------------

For four-star and one-star miRNAs, we performed a KEGG pathway analysis using STRING database online tool, in order to uncover the pathways affected. The analysis has been performed for the refined sets of genes, associated with each of the miRNA sets. All five sets of genes are found to be enriched in pathways relating to microRNAs in cancer (hsa05206). Similarly, all cases except Luminal A were enriched in breast cancer (hsa05224) and pathways in cancer (hsa05200). Moreover, in all except HER2-Enriched subtype, apoptosis (hsa04210) is enriched ([@B53]). Many cancer-related pathways are also enriched in most of the five sets. These are for example the PI3K-Akt signaling pathway (hsa04151), which plays a significant role in tumor proliferation and endocrine resistance in breast cancer ([@B56]; [@B61]), or the well studied p53 pathway \[hsa04115, [@B66]\]. Another example is the MAPK signaling pathway (hsa04010), aberrations in which are present in many tumor types ([@B25]), especially including the Basal-Like breast cancer ([@B28]). Significant pathways related to breast cancer for the four-star and one-star miRNAs are presented in [**Table 5**](#T5){ref-type="table"}. Full information about all enriched pathways is provided in [**Supplementary Table 9**](#SM1){ref-type="supplementary-material"}.

###### 

KEGG pathways significantly enriched in the refined gene set.

  ID         Description                               4-star   LA   LB   HER2-E   BL
  ---------- ----------------------------------------- -------- ---- ---- -------- ----
  hsa05224   Breast cancer                             ✓             ✓    ✓        ✓
  hsa05200   Pathways in cancer                        ✓             ✓    ✓        ✓
  hsa05206   MicroRNAs in cancer                       ✓        ✓    ✓    ✓        ✓
  hsa05202   Transcriptional misregulation in cancer   ✓             ✓             
  hsa04210   Apoptosis                                 ✓        ✓    ✓             ✓
  hsa04215   Apoptosis - multiple species              ✓        ✓         ✓        ✓
  hsa04115   p53 signaling pathway                     ✓             ✓    ✓        ✓
  hsa04151   PI3K-Akt signaling pathway                ✓             ✓    ✓        ✓
  hsa04010   MAPK signaling pathway                    ✓             ✓             ✓
  hsa04110   Cell cycle                                ✓             ✓    ✓        ✓

Selected miRNAs for Gene Ontology Enrichment Analysis {#s3_7}
-----------------------------------------------------

Finally, we analyzed the GO annotations of targeted genes of four-star and one-star miRNAs, also using STRING database. Significantly enriched terms, related to breast cancer, are presented in [**Table 6**](#T6){ref-type="table"}, and the full results of GO enrichment analysis are available in the [**Supplementary Table 10**](#SM1){ref-type="supplementary-material"}. Most importantly, among the enriched biological processes are regulation of cell cycle (GO:0051173) and regulation of cell population proliferation (GO:0010604), that are linked to cancer ([@B79]). These are enriched in the four-star miRNAs and in one-star HER2-E and BL sets, the latter also in the LB set. Among the molecular functions obtained from GO enrichment analysis are chromatin binding (GO:0003682) and protein binding (GO:0005515), significant in the four-star miRNAs, and LB, HER2-E and BL sets. In the one-star LA miRNAs, on the other hand, (GO:0003677) DNA binding and (GO:0019901) protein kinase binding are significantly enriched, both also enriched in the four-star miRNAs. For the four-star miRNAs, most notable significantly enriched cellular components include nucleus (GO:0005634), chromatin (GO:0000785) and heterochromatin (GO:0000792). In the case of one-star miRNAs the nucleus (GO:0005634) was also significantly enriched in all sets, except LA.

###### 

Gene Ontology terms significantly enriched in the refined gene set.

  ID                       Description                                                                               4-star   LA   LB   HER2-E   BL
  ------------------------ ----------------------------------------------------------------------------------------- -------- ---- ---- -------- ----
  GO: Biological Process                                                                                                                         
  GO:0051173               Regulation of cell cycle                                                                  ✓                  ✓        ✓
  GO:0010604               Regulation of cell population proliferation                                               ✓             ✓    ✓        ✓
  GO:0000122               Negative regulation of transcription by RNA polymerase II                                 ✓        ✓    ✓    ✓        
  GO:0010332               Response to gamma radiation                                                               ✓                           
  GO:0045892               Negative regulation of transcription, DNA-templated                                       ✓                  ✓        ✓
  GO:0006974               Cellular response to DNA damage stimulus                                                  ✓        ✓    ✓             ✓
  GO:1902043               Positive regulation of extrinsic apoptotic signaling pathway via death domain receptors                      ✓        
  GO: Molecular Function                                                                                                                         
  GO:0003682               Chromatin binding                                                                         ✓             ✓    ✓        ✓
  GO:0005515               Protein binding                                                                           ✓             ✓    ✓        ✓
  GO:0003677               DNA binding                                                                               ✓        ✓         ✓        
  GO:0019901               Protein kinase binding                                                                    ✓        ✓                  ✓
  GO:0019900               Kinase binding                                                                            ✓                           
  GO:0008139               Nuclear localization sequence binding                                                     ✓                           
  GO:0043565               Sequence-specific DNA binding                                                             ✓             ✓    ✓        
  GO: Cellular Component                                                                                                                         
  GO:0044454               Nuclear chromosome part                                                                   ✓                           ✓
  GO:0005634               Nucleus                                                                                   ✓             ✓    ✓        ✓
  GO:0000785               Chromatin                                                                                 ✓                  ✓        
  GO:0000792               Heterochromatin                                                                           ✓                  ✓        
  GO:0005737               Cytoplasm                                                                                 ✓                  ✓        ✓
  GO:0000803               Sex chromosome                                                                            ✓                           
  GO:0005829               Cytosol                                                                                   ✓                  ✓        ✓

Conclusion {#s4}
==========

In this article, we proposed a method allowing to investigate the miRNAs related to breast cancer, based on Kaplan-Meier survival analysis and expression data obtained from sequencing of miRNAs. This method provides a subset of miRNAs specific to breast cancer subtypes. In particular, using our method, we have identified miRNAs for which increased expression decreases the odds of survival across all subtypes (four-star), and those related in this way only to one subtype (one-star). With the use of four-star miRNAs, we are able to classify patients into tumor and control by achieving 95% average accuracy, while the one-star miRNAs provide maximum of 81% average accuracy for subtype identification over seven machine learning methods. Moreover, the miRNAs described in the stage expression analysis can be the focus of future studies concerning cancer stage progression and its mechanisms. Additionally, investigating the miRNA-Gene-TF networks allowed us to identify miRNAs involved in regulatory circuits, where a miRNA targets and is being targeted by a certain Gene-TF pair. Moreover, PPI network analysis shows known cancer-related proteins, such as TP53, ESR1, BRCA1, MYC and others, which are encoded by genes targeted by some of the four-star and one-star miRNAs, adding to the validity of our study. Furthermore, KEGG pathway and GO enrichment analyses confirmed the biological relevance of our four-star and one-star miRNAs by showing that several pathways, processes and functions known to be associated with breast cancer as their targeted genes are enriched.

The outcome of this research can help to advance the understanding of miRNAs involvement in breast cancer and its subtypes. The key miRNAs can be further tested for use as biomarkers, which are crucial for the development of breast cancer detection and treatment response in the clinical setting ([@B27]). They can also potentially serve as targets for therapeutic modulation, which is a promising application of miRNAs ([@B52]).
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